T(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs

T. Narita, A. Inagaki, T. Kobayashi, Y. Kuroda, T. Fukushima, M. Nezu, S. Fuchida, H. Sakai, N. Sekiguchi, I. Sugiura, Y. Maeda, H. Takamatsu, N. Tsukamoto, D. Maruyama, Y. Kubota, M. Kojima, K. Sunami, T. Ono, M. Ri, K. TobinaiS. Iida

Research output: Contribution to journalLetter

17 Citations (Scopus)
Original languageEnglish
Article numbere285
JournalBlood Cancer Journal
Volume5
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Narita, T., Inagaki, A., Kobayashi, T., Kuroda, Y., Fukushima, T., Nezu, M., Fuchida, S., Sakai, H., Sekiguchi, N., Sugiura, I., Maeda, Y., Takamatsu, H., Tsukamoto, N., Maruyama, D., Kubota, Y., Kojima, M., Sunami, K., Ono, T., Ri, M., ... Iida, S. (2015). T(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer Journal, 5(2), [e285]. https://doi.org/10.1038/bcj.2015.6